摘要 :
The antihyperlipidemic and antioxidant effects of Mentha piperita leaves extracts in Poloxamer 407-induced hyperlipidemic rats were investigated. Antihyperlipidemic activities of hexane, ethyl acetate, and methanol extracts (100, ...
展开
The antihyperlipidemic and antioxidant effects of Mentha piperita leaves extracts in Poloxamer 407-induced hyperlipidemic rats were investigated. Antihyperlipidemic activities of hexane, ethyl acetate, and methanol extracts (100, 200, or 300 mg kg-1 b.w.) were evaluated by lipid profile analysis. Twelve (12) fractions (F1 to F12) were collected from the most antihyperlipidemic extract (ethyl acetate at 100 mg kg-1) and, assayed in vivo for antihyperlipidemic activity. The effects of the most antihyperlipidemic fraction (F2) on redox sensitive biomarkers (SOD, CAT, GSH, MDA) and lipoprotein lipase (LPL) activity at cellular and molecular levels were evaluated. Fraction-2 (F2) was further subjected to GC-MS and LC-MS analysis for identification of nonpolar and polar components. The F2 treatment decreased the level of MDA with concomitant enhancement of GSH, LPL activity in the liver and serum and up regulated the expression of SOD, CAT, and LPL genes in liver and blood relative to the untreated rats.GC-MS and LC-MS revealed oleic acid, vaccenic acid, 3,4-dicaffeoylquinic acid, coumarin, and triacontane as the probable bioactive components with reported antihyperlipidemic and antioxidant effects.
收起
摘要 :
The lowering of serum cholesterol is increasingly recognised as essential in the prevention of coronary heart disease and other atherosclerotic disease. The success of statin trials and the need to deploy these drugs effectively i...
展开
The lowering of serum cholesterol is increasingly recognised as essential in the prevention of coronary heart disease and other atherosclerotic disease. The success of statin trials and the need to deploy these drugs effectively in the population has led increasingly to the identification of many people whose serum cholesterol, triglycerides, and HDL-cholesterol require clinical assessment, and frequently treatment. Lipid disorders are mainly straightforward, but some are complex or resistant to simple treatment strategies. I have reviewed the clinical manifestations of disordered lipid metabolism (dyslipidaemia) and its management.
收起
摘要 :
Whether used as primary or secondary prevention, 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) can lead to a significant reduction in mortality and morbidity from cardiovascular disease. Given the benefit in...
展开
Whether used as primary or secondary prevention, 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) can lead to a significant reduction in mortality and morbidity from cardiovascular disease. Given the benefit in halting atherosclerotic disease progression in patients with stable and acute coronary syndrome, the potential for use in South-Asians remains largely unreported. As this ethnic group has a high rate of coronary events at a younger age, with more extensive and diffuse atheroma, the authors review the impact of statins in relation to observed lipid profiles, as well as novel markers of vascular disease.
收起
摘要 :
Atorvastatin is the more potent drug to treat the hyperlipidemia patients. Unfortunately this drug has got hepatotoxicity and hence the patients on statin treatment have to be monitored for Liver function test frequently. This stu...
展开
Atorvastatin is the more potent drug to treat the hyperlipidemia patients. Unfortunately this drug has got hepatotoxicity and hence the patients on statin treatment have to be monitored for Liver function test frequently. This study is used to find the hepatotoxic effect of atorvastatin in hyperlipidemic patients. This study is planning to do the following biochemical parameters. Glucose ,Urea ,Creatinine , Uric Acid , Sodium , Potassium Chloride , Bicarbonate , Cholesterol , High Density Lipoprotein , Triglycerides , Ratio , Total Bilirubin , Serum Glutamic Pyruvate Transaminase , Alkaline Phosphatase , Gamma-glutamyl transpeptidase , Total Protein , Albumin Globulin.
收起
摘要 :
To evaluate the interference of postprandial lipemia on blood gas parameters and to assess the acid-base status by the quantitative approach of the strong ion model blood samples of 15 healthy dogs were collected during fasting (0...
展开
To evaluate the interference of postprandial lipemia on blood gas parameters and to assess the acid-base status by the quantitative approach of the strong ion model blood samples of 15 healthy dogs were collected during fasting (0 h) and at one (1 h), three (3 h) and five (5 h) hours after the induction of lipemia with a hypercaloric diet. Total cholesterol (TC) and triglyceride (TG) levels were used to assess lipemia and these were correlated with the parameters evaluated accordingly. Anion gap decreased at 5 h without correlation with TC and TG, whereas other parameters measured by the blood gasometer did not change. In the evaluation of the acid base state, the apparent strong ion difference (SIDa) and the strong ion gap (SIG) showed a decrease at 5 h without correlation with lipemia. Lipid levels correlated with the effective strong ion difference (SIDe), the concentration of total non-volatile weak acids (Atot), albumin, phosphate, and magnesium. The SIDe increased at 1 h and at 3 h; the Atot at 1 h, 3 h, and 5 h; albumin increased at 1 h and 3 h; phosphate increased at 1 h, 3 h and 5 h; and magnesium decreased at 5 h. Though postprandial lipemia does not interfere with blood gas analysis, it can cause errors in the variables used to assess the acid-base status, which are dependent on biochemical analytes. Therefore, caution is required when interpreting electrolyte disturbances that result from the postprandial state.
收起
摘要 :
Background and objectives Pitavastatin, a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor (statin), is known as a potent cholesterol-lowering action. However, the efficacy and safety of long-term use of the dru...
展开
Background and objectives Pitavastatin, a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor (statin), is known as a potent cholesterol-lowering action. However, the efficacy and safety of long-term use of the drug for more than 2 years has scarcely been reported. We examined the effectiveness of therapy with pitavastatin, as the only lipid-lowering agent, administered for 36 months.Methods A total of 35 patients with hyperlipidemia (male : female. 21 : 14 ; age, 61.3 ± 12.9 years old ; 17 patients in the cardiovascular high-risk group and 18 in the intermediate-risk group) were treated with pitavastatin at 2 mg daily. Serum lipids and liver enzymes, for safety evaluation, were assessed during and after 36 months' pitavastatin treatment. Results Significant reduction of the serum LDL-C levels was observed after 6 months' therapy in both the high-risk and intermediate-risk groups (high-risk group : 162.3+45.8 mg/dL to 116.9+34.9, intermediate-risk group : 166.7(+-)20.7 to 119.3(+-)38.3 ;P< 0.001 for both.) The rate of successful achievement of the serum LDL-C goal, defined by the Japan Atherosclerosis Society Guideline for the diagnosis and prevention of atherosclerotic cardiovascular diseases for Japanese, was 64.7% and 72.2%, in the high-risk and intermediate-risk group, respectively. The significant reduction of serum lipid levels and high rate of successful achievement of the serum LDL-C goal were maintained until the end of the follow-up period of 36 months. The LDL/HDL ratio reduced by 33.2% and 31.3% from the baseline, and the serum non-HDL-C levels also decreased by 29.8% and 30.1% from the baseline, in the high-risk group and intermediate-risk group, respectively. Pitavastatin was well-tolerated during the observation period.Conclusion Long-term therapy with pitavastatin, as the only lipid-lowering agent, is efficacious and safe for improvement of the lipid profile, suggesting the usefulness of the drug in the prevention of atherosclerosis and cardiovascular events.
收起
摘要 :
To investigate the pathogenesis of hyperlipidemia-induced atherosclerosis, we examined age-dependent changes in platelet activity, blood coagulation and fibrinolysis in susceptibility to a high cholesterol diet (HCD) feeding in ma...
展开
To investigate the pathogenesis of hyperlipidemia-induced atherosclerosis, we examined age-dependent changes in platelet activity, blood coagulation and fibrinolysis in susceptibility to a high cholesterol diet (HCD) feeding in male ICR mice. Pretreatment of platelet-rich-plasma form HCD feeding mice for 3 days wit epinephrine (300μM) resulted in a marked enhancement of adenosine 5'-diphosphate (ADP: 0.1 μM) or collagen (0.7 μg/ml)- stimulated aggregation compared with the same in control mice.
收起
摘要 :
Hypertriglyceridemia (HTG) is a well-established but underestimated cause of acute pancreatitis and recurrent acute pancreatitis. The clinical presentation of HTG-induced pancreatitis (HTG pancreatitis) is similar to other causes....
展开
Hypertriglyceridemia (HTG) is a well-established but underestimated cause of acute pancreatitis and recurrent acute pancreatitis. The clinical presentation of HTG-induced pancreatitis (HTG pancreatitis) is similar to other causes. Pancreatitis secondary to HTG is typically seen in the presence of one or more secondary factors (uncontrolled diabetes, alcoholism, medications, pregnancy) in a patient with an underlying common genetic abnormality of lipoprotein metabolism (familial combined hyperlipidemia or familial HTG). Less commonly, a patient with rare genetic abnormality (familial chylomicronemic syndrome) with or without an additional secondary factor is encountered. The risk of acute pancreatitis in patients with serum triglycerides >1000 and >2000 mg/dL is ～5% and 10% to 20%, respectively. It is not clear whether HTG pancreatitis is more severe than when it is due to other causes. Clinical management of HTG pancreatitis is similar to that of other causes. Insulin infusion in diabetic patients with HTG can rapidly reduce triglyceride (TG) levels. Use of apheresis is still experimental and better designed studies are needed to clarify its role in the management of HTG pancreatitis. Diet, lifestyle changes, and control of secondary factors are key to the treatment, and medications are useful adjuncts to the long-term management of TG levels. Control of TG levels to 500 mg/dL or less can effectively prevent recurrences of pancreatitis.
收起
摘要 :
OBJECTIVES:The research aimed to determine the prevalence and associated factors of uncontrolled hyperlipidemia among Thai patients with the disease and Clinical ASCVD.RESULTS:A total of 1,527 Thai diabetic patients with a history...
展开
OBJECTIVES:The research aimed to determine the prevalence and associated factors of uncontrolled hyperlipidemia among Thai patients with the disease and Clinical ASCVD.RESULTS:A total of 1,527 Thai diabetic patients with a history of ASCVD were included in the study. Uncontrolled hyperlipidemia was detected among 1,216 patients (79.6%; 95% CI 77.6-81.7). The independent factors associated with uncontrolled hyperlipidemia included being female (adjusted odds ratio (AORs); 1.5, 95% CI 1.2-2.0), using thiazolidinedione (AORs; 1.7, 95% CI 1.1-2.7), community hospital (AORs; 4.3, 95% CI 1.0-18.0) and BMI level at 18.5-22.9?kg/m<sup>2</sup> (AORs; 2.2, 95% CI 1.2-4.0), 23.0-24.9?kg/m<sup>2</sup> (AORs; 1.8 95% CI 0.9-3.3), 25.0-29.9?kg/m<sup>2</sup> (AORs; 2.3 95% CI 1.3-4.3) and?≥?30?kg/m<sup>2</sup> (AORs; 2.5 95% CI 1.3-4.9).
收起
摘要 :
Classically, the 3 pillars of atrial fibrillation (AF) management have included anticoagulation for prevention of thromboembolism, rhythm control, and rate control. In both prevention and management of AF, a growing body of eviden...
展开
Classically, the 3 pillars of atrial fibrillation (AF) management have included anticoagulation for prevention of thromboembolism, rhythm control, and rate control. In both prevention and management of AF, a growing body of evidence supports an increased role for comprehensive cardiac risk factor modification (RFM), herein defined as management of traditional modifiable cardiac risk factors, weight loss, and exercise. In this narrative review, we summarize the evidence demonstrating the importance of each facet of RFM in AF prevention and therapy. Additionally, we review emerging data on the importance of weight loss and cardiovascular exercise in prevention and management of AF. (C) 2015 by the American College of Cardiology Foundation.
收起
原文获取